Circular RNA-AnnexinA7 accelerates cisplatin resistance in non-small cell lung cancer via modulating microRNA-545-3p to mediate Cyclin D1

Jian Yao†, Hai Yang Zhang, Shuang Gu, Jin Long Zou, Qiang Zhang and Ri Chu Qu

Department of Thoracic Surgery, Jilin Provincial People's Hospital, Changchun City, Jilin Province, 130021, China

Objective: To explore the mechanism of circular RNA (circRNA)-AnnexinA7 (ANXA7) in non-small cell lung cancer (NSCLC) cisplatin (DDP) resistance through microRNA (miR)-545-3p to target Cyclin D1 (CCND1). Methods: DDP-resistant and non-resistant NSCLC tissues and normal tissues were collected. DDP-resistant cells (A549/DDP and H460/DDP) were constructed. circ-ANXA7, miR-545-3p, CCND1, P-Glycoprotein, and glutathione S-transferase-π in tissues and cells were measured. Analysis of circ-ANXA7 ring structure was performed, as well as detection of circ-ANXA7 distribution in cells. Cell proliferation was detected by MTT and colony formation assay, apoptosis rate was detected by flow cytometry, and cell migration and invasion were evaluated by Transwell assay. The targeting relationship between circ-ANXA7, miR-545-3p and CCND1 was verified. Measurement of tumor volume and quality in mice was performed. Results: Circ-ANXA7 and CCND1 were elevated, while miR-545-3p was suppressed in DDP-resistant NSCLC tissues and cells. Circ-ANXA7 combined with miR-545-3p, which targeted CCND1 to expedite A549/DDP cell proliferation, migration, invasion, DDP resistance, but inhibited cell apoptosis. Conclusion: Circ-ANXA7 enhances DDP resistance in NSCLC via absorbing miR-545-3p to target CCND1 and might be a latent therapeutic target for NSCLC.

Keywords: Circular RNA-AnnexinA7, MicroRNA-545-3p, Cyclin D1, Target binding, A549/cisplatin cells

INTRODUCTION

Lung cancer (LC) is a malignant tumor with the uppermost morbidity and mortality in the world (Zhang et al., 2021). Non-small cell lung cancer (NSCLC) is an extremely critical type of LC, taking up about 85% of LC cases (Xu et al., 2020). Treatment strategies for NSCLC have improved recently, but the 5-year survival rate is still greatly reduced by about 10–15% (Xu et al., 2021). Cisplatin (DDP) chemotherapy is a first-line anti-cancer chemotherapy agent in NSCLC. Nevertheless, patients treated with DDP for a long time develop DDP resistance (Wu et al., 2020). As reported, around 63% of NSCLC patients have DDP resistance (Ye et al., 2020). Consequently, lessening DDP resistance is the crux to ameliorating NSCLC patients’ outcomes. This study was to comprehend latent mechanisms in NSCLC DDP resistance and identify latent biomarkers, offering brand-new insights into NSCLC therapy.

Circular RNAs (circRNAs), a non-coding RNA with closed continuous loops, have been testified to mediate primary or antitumor responses in different cancer treatments (Fan et al., 2021). Notably, numerous circRNAs exert critical roles in multiple biological processes of NSCLC. For instance, circ_PIPE5K1A (Feng et al., 2021), circ-RNF121 (Liu et al., 2021) and circ_0076305 (Wang et al., 2021) have been reported to be implicated in the cancer progression and DDP resistance of NSCLC. Circ-AnnexinA7 (ANXA7), as a member of circRNA, has been reported to expedite lung adenocarcinoma progression (Wang, 2021). In the preliminary experiment, this circRNA was aberrantly modulated in DDP-resistant NSCLC tissues. Nevertheless, the latent impact of circ-ANXA7 on DDP resistance in NSCLC is unknown.

CircularRNA/miRNA/mRNA regulatory network has been adopted to elucidate circRNA’s mechanism in multiple biological processes (Xu et al., 2020). Bioinformatics predicted that miR-545-3p was the target of circ-ANXA7. Recently, miR-545-3p has been reported to participate in NSCLC progression. For instance, blocking circ_0014130 restrains resistance and malignant behaviors of NSCLC cells via modulating miR-545-3p (Du et al., 2021). Circ_0072083 knockdown is involved in DPP-triggered NSCLC tumor inhibition through the miR-545-3p/CBL1L1 axis (Li et al., 2020). Nevertheless, it has not been reported that circ-ANXA7, as a competitive endogenous RNA, combined with miR-545-3p to participate in NSCLC DDP resistance.

Cyclin D1 (CCND1), a recognized cell cycle-associated protein, exerts a crucial action in cell cycle change (Meng et al., 2021). CCND1 is a critical driver of malignant transformation and is frequently elevated in NSCLC, leading to the aberrant proliferation of NSCLC cells (Liu et al., 2020). Notably, modulating CCND1 can alter DDP-resistant cell malignant phenotype (Ju et al., 2020). In this study, it was hypothesized that circ-ANXA7 might participate in NSCLC DDP resistance via miR-545-3p to modulate CCND1.

In this study, 2 DDP-resistant NSCLC cell lines (A549/DDP and H460/DDP) were constructed, and...
circ-ANXA7 was confirmed to modulate DDP-resistant NSCLC cell sensitivity and behavior. Additionally, this research further elucidated the action of circ-ANXA7/miR-545-3p/CCND1 axis in DDP resistance and cancerization of NSCLC.

MATERIALS AND METHODS

Clinical tissue specimen

90 tissue samples were obtained from the School of Medicine, University of Electronic Science and Technology of China, including 30 non-tumor tissue samples from patients with pulmonary laceration repair (control) and 60 NSCLC tissue samples from NSCLC patients with radical resection. Patients with progressive disease (PD) or postoperative recurrence less than 6 months were DDP-resistant, while patients without PD and postoperative recurrence over 12 months were non-resistant. All tissue samples were placed at −80°C. Authorization of the study was performed by the Ethics Committee of the School of Medicine, University of Electronic Science and Technology of China, and written informed consent was obtained from all participants.

Cell culture and transfection

NSCLC cell lines (A549 and H460) were purchased from American Tissue Culture Collection (Manassas, VA), and human bronchial epithelioid cells (HBE-1) were from Bena Culture Collection (Beijing, China). Cells were cultured in Roswell Park Memorial Institute-1640 medium (HyClone, Logan, UT, USA) containing 10% fetal bovine serum, 100 U/ml penicillin and 100 mg/ml streptomycin (Gibco, Carlsbad, CA). DDP-resistant cells (A549/DDP and H460/DDP) were established and grown in a complete medium replenished with DDP (1 µg/ml, Sigma-Aldrich, St. Louis, MO) to maintain resistance. All cells were cultured in 5% CO₂ at 37°C (Pang et al., 2020).

sh-circ-ANXA7, miR-545-3p mimic and inhibitor, as well as corresponding negative controls (sh-NC, mimic-NC, in-NC) were designed and generated (Ribobiotec, Guangzhou, China). CCND1 overexpression plasmid was purchased from ORIGENE, with empty vector (Empty) (Hu et al., 2020). U6 and GAPDH were loading controls.

3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay

A549/DDP cells (5×10⁴/well) were seeded into 96-well plates and cultured overnight. MTT reagent (beyotime) was added at different time points (0, 24, 48, 72 h) and incubated at 37°C for 4 h. Then, 150 µL Dimethyl Sulfoxide was added to each well and 10 min later, optical density at 490 nm was read with a microplate reader (PerkinElmer) (Zhu et al., 2021).

3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay

A549/DDP cells (5×10⁴/well) were seeded into 96-well plates and cultured overnight. MTT reagent (beyotime) was added at different time points (0, 24, 48, 72 h) and incubated at 37°C for 4 h. Then, 150 µL Dimethyl Sulfoxide was added to each well and 10 min later, optical density at 490 nm was read with a microplate reader (PerkinElmer) (Zhu et al., 2021).

Colony formation assay

A549/DDP cells (5×10⁴/well) were seeded in 12-well plates and cultured for 14 d, during which a fresh complete medium was replaced every 3 days and the wells were washed twice with PBS. Then, colonies were fixed in paraformaldehyde (4%, Beyotime), dyed with 0.1% crystal violet (Beyotime) for 2 h, and washed with ddH₂O₃ times. The number of colonies was counted under an inverted microscope (Nikon).

Flow cytometry

A549/DDP cells (1×10⁶ cells/well) after DDP treatment were incubated for 48 h. Cell apoptosis was analyzed by Annexin V-fluorescein isothiocyanate (FITC)/Propidium iodide (PI) assay kit (BestBio, Shanghai, China). In brief, cells were rinsed with cold phosphate-
Vol. 70       297

Circ-ANXA7 and NSCLC

buffered saline (PBS) and incubated with 5 μL Annexin V-FITC and 5 μL PI for 20 min. Ultimately, the assessment of cell apoptosis was implemented on a flow cytometer (FACS Calibur flow cytometer) (Wei et al., 2021).

Transwell migration and invasion analysis

Transwell assay evaluated A549/DDP cell invasion and migration. For migration and invasion measurements, transwell chambers were used without or with Matrigel, respectively (Corning, USA). Cells were prepared at 2×10⁶ cells/mL, then 400 μL cell suspension was inoculated into the upper chamber containing serum-free medium, and 10% PBS was added to the lower chamber. After 24 h of culture, cells in the upper layer were removed with cotton swabs, while those in the lower layer were fixed with methanol for 30 min, stained with 0.1% crystal violet, and counted in five fields under a microscope (Swiss taikang, magnification ×100) (Guo et al., 2022).

Luciferase activity assay

A549/DDP cells were plated on a 24-well plate. circ-ANXA7 or CCND1 3' untranslated region (UTR) (Promega) containing miR-545-3p wild-type (WT) or mutant-type (MUT) binding sites was inserted into the pmirGLO vector (Promega, Madison, WI), and circ-ANXA7/CCND1-WT 3'UTR and circ-ANXA7/CCND1-MUT 3'UTR reporter genes were named. Co-transfection of the corresponding luciferase reporter gene with miR-545-3p mimic or miR-NC was done in A549/DDP cells. After 48 h of incubation, the determination of the luciferase activity was implemented with the luciferase reporter gene kit (Promega) (Guo et al., 2022).

RNA immunoprecipitation (RIP) experiment

Anti-Ago2 (ab252812) and anti-IgG (ab109489) antibodies were utilized for detection. In short, cells were lysed with a lysis buffer and then incubated with protein-g magnetic beads-conjugated anti-Ago2 or IgG at 4°C for 6 h. Microbeads were later collected, and binding RNA was extracted to examine the enrichment of circ-ANXA7 and miR-545-3p (Zhang et al., 2021).

In vivo tumor growth test

The tumor formation experiment was conducted in BALB/c male nude mice (n=24, 6 weeks old, weight of 18–20 g, Huafukang, Beijing, China). A549/DDP cells transfected with sh-Circ-ANXA7, or sh-NC (1×10⁶) were injected subcutaneously into the back of mice. Mice were divided into four groups: sh-NC+PBS, sh-NC+DDP, sh-circ-ANXA7+PBS, and sh-circ-ANXA7+DDP groups. DDP (5 mg/kg) or PBS was injected to measure the tumor volume once a week. After 4 weeks, transplanted tumors from euthanized mice were weighed. Animal treatments were approved by the Animal Research Committee of the School of Medicine, University of Electronic Science and Technology of China (Shao et al., 2021).

Statistical analysis

Statistical software SPSS 21.0 (SPSS, Inc, Chicago, IL, USA) was utilized to analyze data. Kolmogorov-Smirnov test checked the normal distribution of data, and the results were presented as mean ± standard deviation (S.D.). Two-group comparisons were performed using ttest. Comparisons among multiple groups were imple-

Table 1. Primer sequences

<table>
<thead>
<tr>
<th>Genes</th>
<th>Primer sequences (5'–3')</th>
</tr>
</thead>
<tbody>
<tr>
<td>Circ-ANXA7</td>
<td>F: 5'-GCTATCCCCCAACAGGCTAC-3'</td>
</tr>
<tr>
<td></td>
<td>R: 5'-CCTGGTGGGACTCCAATCAT-3'</td>
</tr>
<tr>
<td>MiR-545-3p</td>
<td>F: 5'-TGGCGTCAGCAAACTTATTG-3'</td>
</tr>
<tr>
<td></td>
<td>R: 5'-CCAGTGCAAGGGTCGAGATT-3'</td>
</tr>
<tr>
<td>CCND1</td>
<td>F: 5'-AGCTGTCATCTACCCGAC-3'</td>
</tr>
<tr>
<td></td>
<td>R: 5'-GAATACTGCGGGTGTATTG-3'</td>
</tr>
<tr>
<td>U6</td>
<td>F: 5'-CTCGTCGCGGACAGACA-3'</td>
</tr>
<tr>
<td></td>
<td>R: 5'-AACCGTACGCGCAGCTTCC-3'</td>
</tr>
<tr>
<td>GAPDH</td>
<td>F: 5'-TCCATACACATCTTCCA-3'</td>
</tr>
<tr>
<td></td>
<td>R: 5'-CATACGCCCACAGTTTCC-3'</td>
</tr>
</tbody>
</table>

Note: F, forward; R, reverse.

Figure 1. Circ-ANXA7 is modulated in DDP-resistant NSCLC tissues and cells

(A) RT-qPCR test of circ-ANXA7 in each tissue; (B) RT-qPCR examination of circ-ANXA7 in each cell; (C–D) RNase R and Actinomycin D determination of the stability of circ-ANXA7; (E) RT-qPCR test of the localization of circ-ANXA7 in A549/DDP cells; (F) Kaplan-Meier analysis of the survival prognosis of DDP-resistant NSCLC patients. Data were expressed as mean ± S.D. (Number of samples =3). *P<0.05.
mented with one-way analysis of variance (ANOVA) and pairwise comparison after ANOVA analysis was performed using Fisher’s Least Significant Difference t-test. Enumeration data were shown as rate or percentage and analyzed by Chi-square test. *p<0.05 indicates a significant difference.

RESULTS

Circ-ANXA7 expression is modulated in DDP-resistant NSCLC tissues and cells

circ-ANXA7 levels in resistant and non-resistant NSCLC tissues and normal tissues were tested by RT-qPCR. Compared with non-resistant NSCLC tissues and normal tissues, circ-ANXA7 was elevated in DDP-resistant NSCLC tissues, clarifying that circ-ANXA7 was associated with DDP resistance in NSCLC (Fig. 1A). Subsequently, analysis of the clinicopathological characteristics was implemented. Table 2 elucidated no difference in age, tumor size, gender, and metastasis between DDP-resistant patients with non-resistant patients. Nevertheless, DDP resistant patients had high levels of circ-ANXA7, deep invasion, low rate of tumor metastasis, and poor differentiation.

Likewise, in normal cells (HBE-1), NSCLC cell lines (A549 and H460) and DDP-resistant NSCLC cells (A549/DDP and H460/DDP), it was observed that circ-ANXA7 was the highest in DDP-resistant cells (Fig. 1B).

RNase R analysis and Act D analysis confirmed the annular characteristics of circ-ANXA7, showing that circ-ANXA7 was available to resist RNase R detachment, and its stability was better than linear ANXA7 mRNA (Fig. 1C–D). Additionally, circ-ANXA7 was primarily distributed in NSCLC cell cytoplasm (Fig. 1E). Kaplan-Meier analysis revealed that high circ-ANXA7 was associated with unpleasing overall survival in DDP-resistant NSCLC patients, as presented in Fig. 1F.

To sum up, circ-ANXA7 was stable and elevated in DDP-resistant NSCLC and might be implicated in NSCLC DDP resistance.

Repressive circ-ANXA7 gene is available to suppress NSCLC’s progression and strengthens DDP’s sensitivity

It was found that A549 cells had stronger DDP resistance (Fig. 2A) than H460 cells, and circ-ANXA7 expression in A549 and A549/DDP cells was higher than that in H460 and H460/DDP cells (Fig. 1B), so A549/DDP cells were selected for subsequent studies. As presented in Fig. 2B, circ-ANXA7 was repressed in A549/DDP cells after transfection with sh-circ-ANXA7. Silence of circ-ANXA7 declined DDP IC50 (Fig. 2C). Cell proliferation and apoptosis were subsequently examined, and it was found that circ-ANXA7 gene knockout inhibited the viability of A549/DDP cells (Fig. 2D–E), while the apoptosis rate increased significantly (Fig. 2F). In addition, Tranwell analysis confirmed that circ-ANXA7 silencing effectively blocked A549/DDP cell migration.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Cases</th>
<th>Nonresistant cases (n=30)</th>
<th>Resistant cases (n=30)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (year)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>60 or less</td>
<td>33</td>
<td>17</td>
<td>16</td>
<td>0.859</td>
</tr>
<tr>
<td>More than 60</td>
<td>27</td>
<td>13</td>
<td>14</td>
<td></td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>35</td>
<td>19</td>
<td>16</td>
<td>0.554</td>
</tr>
<tr>
<td>Female</td>
<td>25</td>
<td>11</td>
<td>14</td>
<td></td>
</tr>
<tr>
<td>Circ-ANXA7 level</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.5 fold of control or less</td>
<td>27</td>
<td>19</td>
<td>8</td>
<td>&lt;0.001***</td>
</tr>
<tr>
<td>More than 0.5 fold of control</td>
<td>33</td>
<td>11</td>
<td>22</td>
<td></td>
</tr>
<tr>
<td>Tumor size</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Less than 5 cm</td>
<td>32</td>
<td>18</td>
<td>14</td>
<td>0.355</td>
</tr>
<tr>
<td>5 cm or more</td>
<td>28</td>
<td>12</td>
<td>16</td>
<td></td>
</tr>
<tr>
<td>Distant metastasis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>34</td>
<td>18</td>
<td>16</td>
<td>0.438</td>
</tr>
<tr>
<td>Yes</td>
<td>26</td>
<td>12</td>
<td>14</td>
<td></td>
</tr>
<tr>
<td>Depth of invasion</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N0/N1</td>
<td>26</td>
<td>18</td>
<td>8</td>
<td>0.041*</td>
</tr>
<tr>
<td>N2/N3</td>
<td>34</td>
<td>12</td>
<td>22</td>
<td></td>
</tr>
<tr>
<td>Differentiation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Good/Moderate</td>
<td>31</td>
<td>21</td>
<td>10</td>
<td>0.005**</td>
</tr>
<tr>
<td>Poor</td>
<td>29</td>
<td>9</td>
<td>20</td>
<td></td>
</tr>
</tbody>
</table>

*P<0.05. **P<0.01. ***P<0.001.
and invasion (Fig. 2G–H). Western blot analysis of drug resistance-associated proteins (P-gp and GST-π) was performed, elucidating that P-gp and GST-π in A549/DDP cells were lowered after suppressing circ-ANXA7, as presented in Fig. 2I.

In general, repressing circ-ANXA7 was available to suppress NSCLC progression and strengthened DDP sensitivity.

Circ-ANXA7 performs as a sponge for miR-545-3p

To explore the novel mechanism of circ-ANXA7 to modulate NSCLC, prediction of the target miRNA of circ-ANXA7 was performed on the bioinformatics website starBase. circ-ANXA7 and miR-545-3p had complementary fragments (Fig. 3A). MiR-545-3p in A549/DDP cells was elevated after transfecting miR-545-3p mimic (Fig. 3B). The interaction of miR-545-3p with circ-ANXA7 was verified. As presented in Fig. 3C, elevated miR-545-3p constrained the luciferase activity of circ-ANXA7-WT 3’UTR, but it did not repress that of the mutant construct. Circ-ANXA7 and miR-545-3p were abundant in Ago2 antibody-immunoprecipitated RNA complex, but not in IgG antibody-immunoprecipitated RNA complex (Fig. 3D). Additionally, miR-545-3p expression was downregulated in DDP-resistant NSCLC tissues and cells (Fig. 3E–F), and clinical correlation analysis found that miR-545-3p was negatively associated with circ-ANXA7 in DDP-resistant NSCLC tissues (Fig. 3G).

All in all, miR-545-3p could be modulated by circ-ANXA7.

Suppression of miR-545-3p turns around circ-ANXA7 knockdown’s influence on NSCLC

To determine the functional regulation of circ-ANXA7 and miR-545-3p, sh-circ-ANXA7 and in-miR-545-3p were constructed, and their efficacy was explicitly verified in vitro. It was discovered that silence of circ-ANXA7 elevated miR-545-3p (Fig. 4A). Subsequently, sh-circ-ANXA7 in combination with in-miR-545-3p or in-NC was transfected into A549/DDP cells. As presented in Fig. 4B, transfection with in-miR-545-3p declined miR-545-3p expression. MiR-545-3p expression was suppressed after sh-circ-ANXA7 was blocked by the miR-545-3p inhibitor. Additionally, it was observed that silence of circ-ANXA7 declined DDP IC50 but this effect was suppressed by in-miR-545-3p (Fig. 4C). In the meantime, inhibition of cell viability and promotion of apoptosis by circ-ANXA7 knockdown could be partially reversed by in-miR-545-3p (Fig. 4D–F). Additionally, the introduction of in-miR-545-3p was available to eliminate silenced circ-ANXA7’s suppression of cell invasion and migration (Fig. 4G–H). Reduction in circ-ANXA7 led to a decrease in resistance-associated proteins, and this inhibition could be mitigated by supplementation with in-miR-545-3p (Fig. 4I).

In short, circ-ANXA7 modulated NSCLC cell progression and DDP sensitivity via absorbing miR-545-3p.

MiR-545-3p immediately targets CCND1

As mentioned above, it was attempted to search for miR-545-3p’s direct targets. As presented in Fig. 5A, starBase predicted the common binding site of miR-545-3p and CCND1. In the meantime, miR-545-3p mimic was available to weaken the luciferase activity of CCND1-WT 3’UTR, while no distinct change was presented in the luciferase activity of CCND1-MUT 3’UTR (Fig. 5B). Additionally, circ-ANXA7 and miR-545-3p were abundant in Ago2 antibody immunoprecipitation but not in IgG antibody immunoprecipitation (Fig. 5C). Compared with non-resistant and normal tissues, CCND1 in DDP-
Figure 3. Circ-ANXA7 performs as a sponge for miR-545-3p
(A) Bioinformatics sites forecast of binding sites of circ-ANXA7 with miR-545-3p; (B) RT-qPCR examination of miR-545-3p mimic transfection efficiency; (C–D) Luciferase activity assay and RIP assay assessment of the interaction of circ-ANXA7 with miR-545-3p; (E–F) RT-qPCR test of miR-545-3p in tissues and cells; (G) Pearson correlation analysis evaluation of the association of miR-545-3p with circ-ANXA7. Data were expressed as mean ± S.D. (Number of samples =3). *P<0.05.

Figure 4. Repression of miR-545-3p turns around circ-ANXA7 knockdown’s influence on NSCLC
(A–B) RT-qPCR detection of miR-545-3p in A549/DDP cells after transfection; (C) MTT analysis of IC_{50} of DDP in A549/DDP cells; (D–E) MTT and colony formation assay test of cell proliferative activity; (F) Flow cytometry examination of cell apoptosis; (G–H) Transwell assay examination of cell migration and invasion; (I) Western blot detection of drug-resistance associated proteins (P-gp and GST-π). Data were expressed as mean ± S.D. (Number of samples =3). *P<0.05.
Circ-ANXA7 and NSCLC 

resistant tissues was elevated (Fig. 5D–E). Likewise, CCND1 was also elevated in DDP-resistant NSCLC cells (Fig. 5F–G). In clinical tissues characterized by drug resistance, CCND1 was positively correlated with circ-ANXA7 expression and negatively correlated with miR-545-3p expression (Fig. 5H–I). In A549/DDP cells, downregulation of circ-ANXA7 or overexpression of miR-545-3p decreased CCND1 expression (Fig. 5J).

In brief, CCND1 was miR-545-3p’s downstream gene.

Circ-ANXA7 impacts NSCLC progression and DDP resistance via miR-545-3p/CCND1 axis

Functional tests were performed considering the association of miR-545-3p with circ-ANXA7 or CCND1. CCND1 overexpression plasmid strengthened CCND1 expression in A549/DDP cells (Fig. 6A–B). Then, to explain whether CCND1 mediates the effect of circ-ANXA7 on NSCLC progression and DDP resistance, A549/DDP cells were co-transfected with sh-circ-ANXA7 and CCND1 overexpression plasmid or empty plasmid. As presented in Fig. 6A–B, sh-circ-ANXA7 restrained CCND1 expression, which was reversed after co-transfection with the CCND1 overexpression plasmid. Additionally, the upregulation of CCND1 significantly restored the inhibitory effect of circ-ANXA7 silencing on DDP IC₅₀ and cell viability in A549/DDP cells in vitro (Fig. 6C–E). In the meantime, downregulation of circ-ANXA7 promoted apoptosis, which was eliminated by CCND1 overexpression plasmid (Fig. 6F). Additionally, elevating CCND1 restrained sh-circ-ANXA7-mediated repression of A549/DDP cell migration and invasion (Fig. 6G–H). Additionally, silenced circ-ANXA7-induced suppression of P-gp and GST-π was turned around by overexpressing CCND1 (Fig. 6I).

In short, circ-ANXA7 modulated NSCLC progression and DDP resistance via miR-545-3p/CCND1 axis.

Loss of circ-ANXA7 reduces tumor growth in vivo

After sh-circ-ANXA7 or DDP treatment, tumor volume and weight were reduced, and sh-circ-ANXA7 and DDP treatment were provided with synergistic suppression (Fig. 7A–B). By examining circ-ANXA7 levels in xenografts, sh-Circ-ANXA7 did decrease circ-ANXA7 expression and promote miR-545-3p levels in excised tumors (Fig. 7C). Additionally, loss of circ-ANXA7 repressed CCND1 expression in excised tumors (Fig. 7D–E).

All in all, loss of circ-ANXA7 interacted with DDP therapy, thereby restraining tumor growth in xenograft tumor models.

DISCUSSION

Globally, NSCLC is a deadly cancer with elevated morbidity and mortality (Cao et al., 2021). DDP is the most frequently-adopted chemotherapy drug for the
Nevertheless, DDP resistance severely limits its clinical efficacy (Hong et al., 2020). Consequently, it was crucial to suppress DDP resistance for better treatment of NSCLC patients. It is reported that aberrant circRNA impacts NSCLC cancerization and chemotherapy resistance (Zhang et al., 2021). In this study, it was first discovered that repression of circ-ANXA7 suppressed NSCLC progression and strengthened DDP sensitivity. Additionally, this study first verified the regulatory network of circ-ANXA7/miR-545-3p/CCND1.

Research has shown that the covalent closed structure of circRNAs makes them more stable in eukaryotes (Fu et al., 2021). Likewise, the data displayed that cir-
ANXA7 after RNase R and Actinomycin D treatment was more stable than linear ANXA7. circRNAs exert critical roles in multiple biological processes of NSCLC (Liu et al., 2021). For instance, in DDP-resistant NSCLC tissues and cells, circ_PIP5K1A expression is augmented, while silencing circ_PIP5K1A is available to restrain cancer progression and strengthen DDP sensitivity (Feng et al., 2021). Additionally, silencing circ_0076305 ameliorates the DDP sensitivity of NSCLC (Wang et al., 2021). In other words, circRNAs modulate cancer progression and DDP resistance. This research focused on a novel circRNA (Circ-ANXA7) derived from host gene ANXA7 chr10 (75138745-75138766). Expression analysis testified that elevated CCND1 was presented in DDP-resistant NSCLC tissues and cells, clarifying that circ-ANXA7 might participate in DDP resistance progression in NSCLC. As expected, it was discovered that circ-ANXA7 silencing inhibited the proliferative activity, migration, invasion, and DDP sensitivity of DDP resistant cells, but promoted apoptosis. Overall, the data have illustrated that circ-ANXA7 is a promoter of NSCLC progression and drug resistance. Nevertheless, circ-ANXA7 in patients’ serum was not detected in this study. Notably, a recent report has clarified that exosomes-delivered hsa_circ_0014235 expedites DDP resistance and exacerbates NSCLC development via mediating miR-520a-5p/CDK4 pathway (Xu et al., 2020). Consequently, it was a necessity to further examine circ-ANXA7 in NSCLC clinical sample sequences in subsequent studies, which might offer novel data support for circ-ANXA7 as a promoter of NSCLC resistance.

As reported, the regulatory function of circRNA is associated with the miRNA/mRNA signaling network (Feng et al., 2021). Notably, it is reported that circRNAs participate in various human cancers via effectively targeting miRNA to mediate gene (Liu et al., 2022). For instance, silencing circ_0007385 restricts malignant behavior and DDP resistance of NSCLC cells via miR-519d-3p/HMG1 axis (Ye et al., 2020). Circ_0076305 modulates STAT3 and DDP resistance of NSCLC cells via absorbing miR-296-5p as a sponge (Dong et al., 2019). Consequently, miR-545-3p was discovered to have a targeted binding site with circ-ANXA7. Forgoing studies have elucidated that miR-545-3p is silenced in NSCLC and performs as a tumor suppressor gene, restraining NSCLC progression and strengthening DDP sensitivity (Du et al., 2021; Li, Liu, and Qin 2020). Likewise, in this study, it was discovered that miR-545-3p was silenced in DDP-resistant NSCLC tissues and cells and performed as a tumor suppressor gene. Additionally, it was first discovered that miR-545-3p was competitively adsorbed by circ-ANXA7, and upregulating miR-545-3p reversed the inhibitory effect of circ-ANXA7 loss on NSCLC progression and DDP resistance.

miRNAs are available to repress specific proteins after transcription via combining with the 3’UTR of target mRNA (Pang et al., 2020). Consequently, the target genes of miR-545-3p were predicted, and CCND1 among numerous miRNAs has drawn our attention due to its relationship with DDP resistance (Zuo et al., 2021). CCND1 performs as a carcinogen in NSCLC, promoting proliferation, migration, invasion, and drug resistance of NSCLC cells, and may become a potential therapeutic target for NSCLC (Huang et al., 2020; Cui et al., 2020; Liu et al., 2020). Nevertheless, the mechanism of circ-ANXA7/miR-545-3p/CCND1 axis in NSCLC DDP resistance has not been explored. In this research, it was testified that elevated CCND1 was presented in DDP-resistant NSCLC tissues and cells. Additionally, it was first discovered that miR-545-3p was implicated in DDP resistance in NSCLC via targeting CCND1.

In brief, circ-ANXA7 accelerated DDP resistance in NSCLC via the miR-545-3p/CCND1 axis, which might offer brand-new insights into the treatment of DDP resistance in NSCLC. Nevertheless, the potential involvement of downstream pathways was not considered in this study. In addition, future multicenter and animal studies are needed to further elucidate the role of circ-ANXA7 in DDP resistance in NSCLC.

Declarations

Data availability. The figures and tables used to support the findings of this study are included in the article. Conflicts of interest. The authors declare that they have no conflicts of interest.

Acknowledgements. The authors would like to show sincere thanks to those techniques who have contributed to this research.

REFERENCES


